Cardiotocography in the Prognosis of Perinatal Outcome

Bogdanović, Gordana; Babović, Adnan; Rizvanovic, Mirzeta; Ljuca, Dženita; Grgić, Gordana; Djuranovic-Milicic, Jadranaka

doi:10.5455/medarh.2014.68.102-105

Cited by 36 publications

(29 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with the HII hypothesis that stuttering is associated with transient decrements in brain perfusion, hypoxic-ischemic states are also associated with decreased HR [46]. …”

Section: Implications For Understanding Stutteringsupporting

confidence: 51%

Toward a Theory of Stuttering

Mawson

Radford

Jacob³

2016

Eur Neurol

View full text Add to dashboard Cite

Stuttering affects about 1% of the general population and from 8 to 11% of children. The onset of persistent developmental stuttering (PDS) typically occurs between 2 and 4 years of age. The etiology of stuttering is unknown and a unifying hypothesis is lacking. Clues to the pathogenesis of stuttering include the following observations: PDS is associated with adverse perinatal outcomes and birth-associated trauma; stuttering can recur or develop in adulthood following traumatic events such as brain injury and stroke; PDS is associated with structural and functional abnormalities in the brain associated with speech and language; and stuttering resolves spontaneously in a high percentage of affected children. Evidence marshaled from the literature on stuttering and from related sources suggests the hypothesis that stuttering is a neuro-motor disorder resulting from perinatal or later-onset hypoxic-ischemic injury (HII), and that chronic stuttering and its behavioral correlates are manifestations of recurrent transient ischemic episodes affecting speech-motor pathways. The hypothesis could be tested by comparing children who stutter and nonstutterers (controls) in terms of the occurrence of perinatal trauma, based on birth records, and by determining rates of stuttering in children exposed to HII during the perinatal period. Subject to testing, the hypothesis suggests that interventions to increase brain perfusion directly could be effective both in the treatment of stuttering and its prevention at the time of birth or later trauma.

show abstract

“…Consistent with the HII hypothesis that stuttering is associated with transient decrements in brain perfusion, hypoxic-ischemic states are also associated with decreased HR [46]. …”

Section: Implications For Understanding Stutteringsupporting

confidence: 51%

Toward a Theory of Stuttering

Mawson

Radford

Jacob³

2016

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…We have to take into consideration the difficulty of applying a preventative measure at the exact time of injury in a clinical setting. Nevertheless, although formal randomized clinical trials have not been performed on this drug, its safety profile is high (5, 26), so we can envision a scenario where MB is used as a therapeutic option in cases with a high risk of developing perinatal asphyxia (6,33).…”

Section: Discussionmentioning

confidence: 99%

Methylene blue prevents retinal damage in an experimental model of ischemic proliferative retinopathy

Rey-Funes

Larráyoz

Fernández

et al. 2016

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

-Perinatal asphyxia induces retinal lesions, generating ischemic proliferative retinopathy, which may result in blindness. Previously, we showed that the nitrergic system was involved in the physiopathology of perinatal asphyxia. Here we analyze the application of methylene blue, a well-known soluble guanylate cyclase inhibitor, as a therapeutic strategy to prevent retinopathy. Male rats (n ϭ 28 per group) were treated in different ways: 1) control group comprised born-to-term animals; 2) methylene blue group comprised animals born from pregnant rats treated with methylene blue (2 mg/kg) 30 and 5 min before delivery; 3) perinatal asphyxia (PA) group comprised rats exposed to perinatal asphyxia (20 min at 37°C); and 4) methylene blue-PA group comprised animals born from pregnant rats treated with methylene blue (2 mg/kg) 30 and 5 min before delivery, and then the pups were subjected to PA as above. For molecular studies, mRNA was obtained at different times after asphyxia, and tissue was collected at 30 days for morphological and biochemical analysis. Perinatal asphyxia produced significant gliosis, angiogenesis, and thickening of the inner retina. Methylene blue treatment reduced these parameters. Perinatal asphyxia resulted in a significant elevation of the nitrergic system as shown by NO synthase (NOS) activity assays, Western blotting, and (immuno)histochemistry for the neuronal isoform of NOS and NADPH-diaphorase activity. All these parameters were also normalized by the treatment. In addition, methylene blue induced the upregulation of the anti-angiogenic peptide, pigment epithelium-derived factor. Application of methylene blue reduced morphological and biochemical parameters of retinopathy. This finding suggests the use of methylene blue as a new treatment to prevent or decrease retinal damage in the context of ischemic proliferative retinopathy. retina; nitric oxide; ischemic proliferative retinopathy; methylene blue; angiogenesis PERINATAL ASPHYXIA (PA) is one of the most severe problems in perinatology services across the world (9,15,23,27). PA generates a transient global hypoxia-ischemia status that damages the brain, spinal cord, and retina (14, 17, 39, 52). The degree and the length of perinatal asphyxia are decisive for the development of injury sequelae, such as attention-deficit hyperactivity disorder (1), epilepsy, mental retardation, spasticity, and visual or hearing alterations (61). One third of asphyctic neonates develop serious long-term neurological injuries including several degrees of ischemic proliferative retinopathy (IPR) and even blindness (20).In rats, the retina is particularly sensitive to oxygen alterations (56), and the morphological changes observed in its inner layers are compatible with some alterations observed in human diseases such as retinopathy in diabetes, retinal vein occlusion, and retinopathy of prematurity (ROP), an avoidable cause of visual impairment and blindness in children (20, 61). The changes observed in asphyctic animals include ganglion cell degeneration, n...

show abstract

“…297,298 In low resource settings, abnormal fetal heart rate can be detected, although this alone is not as sensitive as cardiotocography. 9,299 The company Laerdal developed a fetal heart rate monitor, Moyo, for low-resource settings; Moyo is sold for less than $200.…”

Section: Diagnostics For Neonatal Healthmentioning

confidence: 99%

“…297 A lack of oxygen and increase in carbon dioxide leads to metabolic acidosis, which results in low pH in cases of asphyxia. 298 In addition to pH, the base excess of umbilical cord blood provides an indication of prolonged asphyxia, and the APGAR score determines severity.…”

Section: Diagnostics For Neonatal Healthmentioning

confidence: 99%

“…298 In addition to pH, the base excess of umbilical cord blood provides an indication of prolonged asphyxia, and the APGAR score determines severity. 297,298,303,304 APGAR is a symptomatic-based scoring system based on Appearance, Pulse, Grimace, Activity, and Respiration. 296 A pH value less than 7, a base deficit greater than 12 mmol/L, and an APGAR score from 0–3 indicate asphyxia.…”

Section: Diagnostics For Neonatal Healthmentioning

confidence: 99%

See 1 more Smart Citation

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

et al. 2017

View full text Add to dashboard Cite

Each day, approximately 830 women and 7,400 newborns die from complications during pregnancy and childbirth. Improving maternal and neonatal health will require bringing rapid diagnosis and treatment to the point of care in low-resource settings. However, to date there are few diagnostic tools available that can be used at the point of care to detect the leading causes of maternal and neonatal mortality in low-resource settings. Here we review both commercially available diagnostics and technologies that are currently in development to detect the leading causes of maternal and neonatal mortality, highlighting key gaps in development where innovative design could increase access to technology and enable rapid diagnosis at the bedside.

show abstract

Cardiotocography in the Prognosis of Perinatal Outcome

Cited by 36 publications

References 10 publications

Toward a Theory of Stuttering

Toward a Theory of Stuttering

Methylene blue prevents retinal damage in an experimental model of ischemic proliferative retinopathy

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

Contact Info

Product

Resources

About